BioAtla (BCAB) Stock Forecast, Price Target & Predictions
BCAB Stock Forecast
BioAtla stock forecast is as follows: an average price target of $5.00 (represents a 622.23% upside from BCAB’s last price of $0.69) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BCAB Price Target
The average price target for BioAtla (BCAB) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 622.23% upside from BCAB's last price of $0.69.
BCAB Analyst Ratings
According to 1 Wall Street analysts, BioAtla's rating consensus is 'Buy'. The analyst rating breakdown for BCAB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioAtla Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 23, 2024 | Reni Benjamin | JMP Securities | $5.00 | $2.28 | 119.30% | 622.23% |
The latest BioAtla stock forecast, released on May 23, 2024 by Reni Benjamin from JMP Securities, set a price target of $5.00, which represents a 119.30% increase from the stock price at the time of the forecast ($2.28), and a 622.23% increase from BCAB last price ($0.69).
BioAtla Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $0.69 | $0.69 | $0.69 |
| Upside/Downside | -100.00% | -100.00% | 622.23% |
In the current month, the average price target of BioAtla stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioAtla's last price of $0.69. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 23, 2024 | JMP Securities | Outperform | Outperform | Hold |
BioAtla's last stock rating was published by JMP Securities on May 23, 2024. The company gave BCAB a "Outperform" rating, the same as its previous rate.
BioAtla Financial Forecast
BioAtla Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $250.00K | - | $250.00K |
| Avg Forecast | $3.68M | $4.58M | $5.70M | $7.10M | $8.84M | $11.00M | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| High Forecast | $3.68M | $4.58M | $5.70M | $7.10M | $8.84M | $11.00M | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| Low Forecast | $3.68M | $4.58M | $5.70M | $7.10M | $8.84M | $11.00M | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | - | 1.47% |
BioAtla's average Quarter revenue forecast for Mar 22 based on 1 analysts is $250.00K, with a low forecast of $250.00K, and a high forecast of $250.00K. BCAB's average Quarter revenue forecast represents a 0.00% decrease compared to the company's last Quarter revenue of $250.00K (Dec 21).
BioAtla EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.54M | $-25.48M | $-28.62M | $-23.94M | $-22.79M | $-22.47M | $-30.05M |
| Avg Forecast | $-735.69K | $-915.89K | $-1.14M | $-1.42M | $-1.77M | $-2.20M | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-25.33M | $-920.00K | $-2.20M | $-34.00K |
| High Forecast | $-735.69K | $-915.89K | $-1.14M | $-1.42M | $-1.77M | $-2.20M | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-20.26M | $-920.00K | $-2.20M | $-34.00K |
| Low Forecast | $-735.69K | $-915.89K | $-1.14M | $-1.42M | $-1.77M | $-2.20M | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-30.39M | $-920.00K | $-2.20M | $-34.00K |
| Surprise % | - | - | - | - | - | - | - | - | 91.81% | 272.99% | 429.27% | 0.95% | 24.78% | 10.23% | 883.94% |
undefined analysts predict BCAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than BioAtla's previous annual EBITDA (undefined) of $NaN.
BioAtla Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-27.76M | $-25.41M | $-28.76M | $-24.16M | - | $-22.93M | $-30.38M |
| Avg Forecast | $-19.01M | $-19.01M | $-18.05M | $-18.85M | $-18.61M | $-19.98M | $-21.60M | $-38.31M | $-35.10M | $-38.60M | $-33.09M | $-25.66M | $-27.97M | $-31.06M | $-40.77M |
| High Forecast | $-19.01M | $-19.01M | $-18.05M | $-18.85M | $-18.06M | $-19.98M | $-21.60M | $-32.11M | $-35.10M | $-38.60M | $-33.09M | $-20.53M | $-27.97M | $-31.06M | $-40.77M |
| Low Forecast | $-19.01M | $-19.01M | $-18.05M | $-18.85M | $-19.16M | $-19.98M | $-21.60M | $-41.69M | $-35.10M | $-38.60M | $-33.09M | $-30.79M | $-27.97M | $-31.06M | $-40.77M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | 0.66% | 0.87% | 0.94% | - | 0.74% | 0.75% |
BioAtla's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioAtla SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $6.69M | $6.34M | $8.34M | $7.42M | $30.04M | $7.14M | $15.86M |
| Avg Forecast | $133.76M | $166.52M | $207.31M | $258.08M | $321.29M | $399.99M | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| High Forecast | $133.76M | $166.52M | $207.31M | $258.08M | $321.29M | $399.99M | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| Low Forecast | $133.76M | $166.52M | $207.31M | $258.08M | $321.29M | $399.99M | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| Surprise % | - | - | - | - | - | - | - | - | 0.12% | 0.37% | 0.69% | 0.82% | 0.18% | 0.02% | 2.57% |
BioAtla's average Quarter SG&A projection for Dec 23 is $545.44M, based on 2 Wall Street analysts, with a range of $545.44M to $545.44M. The forecast indicates a 8057.91% rise compared to BCAB last annual SG&A of $6.69M (Dec 22).
BioAtla EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | - | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.58 | $-0.68 | $-0.77 | $-0.65 | - | $-0.68 | $-0.90 |
| Avg Forecast | $-0.39 | $-0.39 | $-0.37 | $-0.39 | $-0.39 | $-0.41 | $-0.45 | $-0.79 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| High Forecast | $-0.39 | $-0.39 | $-0.37 | $-0.39 | $-0.37 | $-0.41 | $-0.45 | $-0.66 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| Low Forecast | $-0.39 | $-0.39 | $-0.37 | $-0.39 | $-0.40 | $-0.41 | $-0.45 | $-0.86 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| Surprise % | - | - | - | - | - | - | - | - | 0.80% | 0.85% | 1.12% | 0.99% | - | 1.06% | 1.06% |
According to undefined Wall Street analysts, BioAtla's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCAB previous annual EPS of $NaN (undefined).
BioAtla Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| OLMA | Olema Pharmaceuticals | $6.14 | $27.00 | 339.74% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| BCAB | BioAtla | $1.31 | $5.00 | 281.68% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| NAUT | Nautilus Bio | $1.98 | $6.00 | 203.03% | Buy |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |